Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Tirzepatide

STRIDES

Eli Lilly · Phase 2 · Terminated · Enrollment 204

NCT06515418

Participants reaching a weight loss threshold

Participants reaching threshold, %

Source: Cited trial source. The denominator is the source figure, when it states one.

No selected arm reports a responder percent.

Show as table
Arm≥5%≥10%≥15%≥20%
A: Tirzepatide Monotherapyn/rn/rn/rn/r
B: Azelaprag once daily plus Tirzepatiden/rn/rn/rn/r
C: Azelaprag twice daily plus Tirzepatiden/rn/rn/rn/r
D: Azelaprag Monotherapyn/rn/rn/rn/r

Not shown

  • A: Tirzepatide Monotherapy: endpoint not reported
  • B: Azelaprag once daily plus Tirzepatide: endpoint not reported
  • C: Azelaprag twice daily plus Tirzepatide: endpoint not reported
  • D: Azelaprag Monotherapy: endpoint not reported